JP2018115201A5 - - Google Patents

Download PDF

Info

Publication number
JP2018115201A5
JP2018115201A5 JP2018061990A JP2018061990A JP2018115201A5 JP 2018115201 A5 JP2018115201 A5 JP 2018115201A5 JP 2018061990 A JP2018061990 A JP 2018061990A JP 2018061990 A JP2018061990 A JP 2018061990A JP 2018115201 A5 JP2018115201 A5 JP 2018115201A5
Authority
JP
Japan
Prior art keywords
atoms
substituted
unsubstituted
unbranched
branched alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018061990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018115201A (ja
JP6763904B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018115201A publication Critical patent/JP2018115201A/ja
Publication of JP2018115201A5 publication Critical patent/JP2018115201A5/ja
Application granted granted Critical
Publication of JP6763904B2 publication Critical patent/JP6763904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018061990A 2011-05-23 2018-03-28 ピリジン−及びピラジン誘導体 Expired - Fee Related JP6763904B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488997P 2011-05-23 2011-05-23
US61/488,997 2011-05-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016124235A Division JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体

Publications (3)

Publication Number Publication Date
JP2018115201A JP2018115201A (ja) 2018-07-26
JP2018115201A5 true JP2018115201A5 (enExample) 2020-08-13
JP6763904B2 JP6763904B2 (ja) 2020-09-30

Family

ID=45976540

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014512837A Expired - Fee Related JP6054954B2 (ja) 2011-05-23 2012-04-11 ピリジン−及びピラジン誘導体
JP2016124235A Pending JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体
JP2018061990A Expired - Fee Related JP6763904B2 (ja) 2011-05-23 2018-03-28 ピリジン−及びピラジン誘導体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014512837A Expired - Fee Related JP6054954B2 (ja) 2011-05-23 2012-04-11 ピリジン−及びピラジン誘導体
JP2016124235A Pending JP2016196492A (ja) 2011-05-23 2016-06-23 ピリジン−及びピラジン誘導体

Country Status (22)

Country Link
US (1) US9273029B2 (enExample)
EP (1) EP2714677B1 (enExample)
JP (3) JP6054954B2 (enExample)
KR (1) KR101581522B1 (enExample)
CN (1) CN103748086B (enExample)
AU (1) AU2012259333B2 (enExample)
BR (1) BR112013029640A2 (enExample)
CA (1) CA2832605C (enExample)
DK (1) DK2714677T3 (enExample)
EA (1) EA023364B1 (enExample)
ES (1) ES2699256T3 (enExample)
HR (1) HRP20181884T1 (enExample)
IL (1) IL229528A (enExample)
LT (1) LT2714677T (enExample)
MX (1) MX352975B (enExample)
PL (1) PL2714677T3 (enExample)
PT (1) PT2714677T (enExample)
RS (1) RS58015B1 (enExample)
SG (1) SG194105A1 (enExample)
SI (1) SI2714677T1 (enExample)
WO (1) WO2012161877A1 (enExample)
ZA (1) ZA201307429B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2714677T (lt) * 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
HUE037134T2 (hu) * 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9758505B2 (en) 2014-02-12 2017-09-12 Iteos Therapeutics 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2016057338A1 (en) * 2014-10-06 2016-04-14 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
BR112017019699A2 (pt) 2015-03-17 2018-09-04 Pfizer Inc. derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
KR102359707B1 (ko) 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
MA49068B1 (fr) * 2017-04-27 2023-07-31 Ishihara Sangyo Kaisha Composé n-(4-pyridyl) nicotinamide ou sel de celui-ci
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
IL298767A (en) 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
IL301991A (en) * 2020-10-09 2023-06-01 Napa Therapeutics Ltd Heteroaryl amide inhibitors for CD38
CN116099004B (zh) * 2022-12-30 2024-01-30 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗膀胱癌的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
EP1715867A4 (en) * 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
PL3354650T3 (pl) * 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
GB0903759D0 (en) * 2009-03-04 2009-04-15 Medical Res Council Compound
US8198285B2 (en) * 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
LT2714677T (lt) * 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai

Similar Documents

Publication Publication Date Title
JP2016196492A5 (enExample)
JP2019031560A5 (enExample)
JP2009531322A5 (enExample)
JP2010532768A5 (enExample)
JP2016506369A5 (enExample)
JP2016526558A5 (enExample)
JP2016530259A5 (enExample)
JP2016515560A5 (enExample)
JP2016056183A5 (enExample)
JP2016503797A5 (enExample)
JP2014518884A5 (enExample)
JP2016513660A5 (enExample)
JP2015511613A5 (enExample)
JP2015515961A5 (enExample)
JP2011530545A5 (enExample)
JP2012092103A5 (enExample)
JP2019500387A5 (enExample)
JP2015508103A5 (enExample)
JP2013544276A5 (enExample)
JP2015517574A5 (enExample)
JP2007514773A5 (enExample)
JP2012530758A5 (enExample)
JP2017537937A5 (enExample)
JP2017501237A5 (enExample)
JP2020097596A5 (enExample)